ASXL1 and acute myeloid leukemia: A study by Ohgami et al. on 93 AML patients also showed that the prevalence of ASXL1 mutations in AML patients with myelodysplasia-related changes (AML-MRC) was higher than in patients with not otherwise specified therapy-related AML (AML-T, AML-NOS) and those with recurrent genetic abnormalities (AML-RGA) (39).